Heart Test Laboratories (Heart Test Laboratories) Land And Improvements : $0.00 Mil (As of Jan. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Heart Test Laboratories Land And Improvements?

Heart Test Laboratories's land and improvements for the quarter that ended in Jan. 2024 was $0.00 Mil.

Heart Test Laboratories Land And Improvements Historical Data

The historical data trend for Heart Test Laboratories's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heart Test Laboratories Land And Improvements Chart

Heart Test Laboratories Annual Data

Trend

Apr20

Apr21

Apr22

Apr23

Land And Improvements

Heart Test Laboratories Quarterly Data
	Apr20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Land And Improvements	Get a 7-Day Free Trial									-	-	-	-	-

Heart Test Laboratories Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Heart Test Laboratories (Heart Test Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heart Test Laboratories Inc (NAS:HSCS) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

550 Reserve Street, Suite 360, Southlake, TX, USA, 76092

Website

https://www.heartsciences.com

Heart Test Laboratories Inc is a medical technology company focused on applying innovative AI-based technology to an ECG to expand and improve an ECG's clinical usefulness. The objective of the company is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.

Executives

David R. Wells	director	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent	director	750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz	director, officer: See Remarks	3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson	officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson	director, officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092